News
CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback